Physician profile
Casey E Mccain
NPI 1528294741
$6,965.93
in general payments reported to CMS, 2019-2025
21 companies · $673 in 2025
The $673 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,081 · 2020: $1,203 · 2021: $1,171 · 2022: $1,183 · 2023: $881 · 2024: $774 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,518.77 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,267.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,130.48 | 2021-2025 | |
| Vertiflex, INC. | $372.83 | 2019 | |
| Inspire Medical Systems, INC. | $300.58 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $231.81 | 2019-2024 | |
| Allergan, INC. | $221.85 | 2019-2020 | |
| Boston Scientific Corporation | $201.61 | 2020-2021 | |
| Eisai INC. | $131.71 | 2020-2021 | |
| Abbott Laboratories | $93.55 | 2022-2023 | Freestyle Libre 3 |
| Vertex Pharmaceuticals Incorporated | $84.29 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $80.45 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $67.63 | 2020-2024 | Contrave, Nexletol, Nexlizet |
| Pfizer INC. | $58.98 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.52 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $44.42 | 2019 | |
| Saluda Medical Americas, INC. | $39.52 | 2023 | Evoke Scs |
| Amgen INC. | $23.90 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $23.36 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $16.22 | 2020 | |
| Merck Sharp & Dohme LLC | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Mccain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.